{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T16:45:10Z","timestamp":1778863510718,"version":"3.51.4"},"reference-count":13,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2022,10,22]],"date-time":"2022-10-22T00:00:00Z","timestamp":1666396800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"ViiV Healthcare Europe"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,1,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>We aimed to investigate and compare the efficacy and safety of two dolutegravir-based two-drug regimens: dolutegravir\u200a+\u200alamivudine versus dolutegravir\u200a+\u200arilpivirine.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We analysed a cohort of people living with HIV (PLWHIV) switching to dolutegravir\u200a+\u200alamivudine or dolutegravir\u200a+\u200arilpivirine. We excluded from the analysis PLWHIV with no available pre-switch genotypic test or with a known resistance mutation to one of the study drugs. We evaluated incidence of virological failure (VF) and treatment discontinuation (TD), as well as changes in immunological and metabolic parameters.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We enrolled 592 PLWHIV: 306 in the lamivudine group and 286 in the rilpivirine group. We observed nine VFs in the lamivudine group [1.4\u2005VF per 100\u2005patient-years of follow-up (PYFU)] and four VFs in the rilpivirine group (0.6\u2005VF per 100\u2005PYFU). Subsequent genotypic analysis showed no acquired resistance-associated mutations in those experiencing VF. Estimated probability of maintaining virological suppression at 144 and 240\u2005weeks were 96.6% and 92.7%, respectively, in the lamivudine group and 98.7% and 98.7%, respectively, in the rilpivirine group (log-rank P\u200a=\u200a0.172). The estimated probability of maintaining study regimen at Week 240 was 82.3% in the lamivudine group and 85.9% in the rilpivirine group (log-rank P\u200a=\u200a0.018). We observed a significant improvement in CD4+ cell count at Week 240 in the lamivudine group (P\u200a=\u200a0.012); in the rilpivirine group we registered a significant increase in CD4\/CD8 ratio (P\u200a=\u200a0.014).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Both analysed strategies are effective and safe as switch strategies in clinical practice, with a low incidence of VF and a favourable immunological recovery, even in the long term.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkac362","type":"journal-article","created":{"date-parts":[[2022,10,22]],"date-time":"2022-10-22T16:57:47Z","timestamp":1666457867000},"page":"117-121","source":"Crossref","is-referenced-by-count":10,"title":["Analysing the efficacy and tolerability of dolutegravir plus either rilpivirine or lamivudine in a multicentre cohort of virologically suppressed PLWHIV"],"prefix":"10.1093","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5941-883X","authenticated-orcid":false,"given":"A","family":"Ciccullo","sequence":"first","affiliation":[{"name":"Unit of Infectious Diseases, San Salvatore Hospital , L\u2019Aquila , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4623-9976","authenticated-orcid":false,"given":"G","family":"Baldin","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases, Fondazione Policlinico Universitario A. Gemelli IRCCS , Rome , Italy"},{"name":"Mater Olbia Hospital , Olbia , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V","family":"Borghi","sequence":"additional","affiliation":[{"name":"Azienda Ospedaliero Universitaria di Modena, Clinica Malattie Infettive e Tropicali , Modena , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M V","family":"Cossu","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Infectious Diseases, Luigi Sacco University Hospital , Milan , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3685-4289","authenticated-orcid":false,"given":"A","family":"Giacomelli","sequence":"additional","affiliation":[{"name":"UOC Malattie Infettive III, DIBIC Luigi Sacco, University of Milan , Milan , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F","family":"Lagi","sequence":"additional","affiliation":[{"name":"Division of Tropical and Infectious Diseases, \u2018Careggi\u2019 Hospital , Florence , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9106-7742","authenticated-orcid":false,"given":"D","family":"Farinacci","sequence":"additional","affiliation":[{"name":"Catholic University of the Sacred Heart , Rome , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V","family":"Iannone","sequence":"additional","affiliation":[{"name":"Catholic University of the Sacred Heart , Rome , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R A","family":"Passerotto","sequence":"additional","affiliation":[{"name":"Catholic University of the Sacred Heart , Rome , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Capetti","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Infectious Diseases, Luigi Sacco University Hospital , Milan , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0385-0903","authenticated-orcid":false,"given":"G","family":"Sterrantino","sequence":"additional","affiliation":[{"name":"Division of Tropical and Infectious Diseases, \u2018Careggi\u2019 Hospital , Florence , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Mussini","sequence":"additional","affiliation":[{"name":"Azienda Ospedaliero Universitaria di Modena, Clinica Malattie Infettive e Tropicali , Modena , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0569-9407","authenticated-orcid":false,"given":"S","family":"Antinori","sequence":"additional","affiliation":[{"name":"UOC Malattie Infettive III, DIBIC Luigi Sacco, University of Milan , Milan , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Di Giambenedetto","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases, Fondazione Policlinico Universitario A. Gemelli IRCCS , Rome , Italy"},{"name":"Catholic University of the Sacred Heart , Rome , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,10,22]]},"reference":[{"key":"2023010801140837900_dkac362-B1","author":"European AIDS Clinical Society","year":"2021."},{"key":"2023010801140837900_dkac362-B2"},{"key":"2023010801140837900_dkac362-B3","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/QAI.0000000000002449","article-title":"Brief report: durable suppression and low rate of virologic failure 3 years after switch to dolutegravir + rilpivirine 2-drug regimen: 148-week results from the SWORD-1 and SWORD-2 randomized clinical trials","volume":"85","author":"van Wyk","year":"2020","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2023010801140837900_dkac362-B4","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciac130","article-title":"Efficacy and safety of switching to the 2-drug regimen dolutegravir\/lamivudine versus continuing a 3- or 4-drug regimen for maintaining virologic suppression in adults living with HIV-1: week 48 results from the phase 3, non-inferiority SALSA randomized trial","author":"Llibre","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2023010801140837900_dkac362-B5","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciac036","article-title":"Efficacy and safety of switching to dolutegravir\/lamivudine (DTG\/3TC) versus continuing a tenofovir alafenamide-based 3- or 4-drug regimen for maintenance of virologic suppression in adults living with HIV-1: results through week 144 from the phase 3, non-inferiority TANGO randomized trial","volume":"75","author":"Osiyemi","year":"2022;","journal-title":"Clin Infect Dis"},{"key":"2023010801140837900_dkac362-B6","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1177\/1060028018761600","article-title":"Dolutegravir plus rilpivirine as a switch option in cART-experienced patients: 96-week data","volume":"52","author":"Capetti","year":"2018;","journal-title":"Ann Pharmacother"},{"key":"2023010801140837900_dkac362-B7","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1097\/QAI.0000000000002787","article-title":"Five years with dolutegravir plus lamivudine as a switch strategy: much more than a positive finding","volume":"88","author":"Ciccullo","year":"2021;","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2023010801140837900_dkac362-B8","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3851\/IMP3270","article-title":"A comparison between two dolutegravir-based two-drug regimens as switch strategies in a multicentre cohort of HIV-1-infected patients","volume":"24","author":"Ciccullo","year":"2019;","journal-title":"Antivir Ther"},{"key":"2023010801140837900_dkac362-B9","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1128\/CMR.00015-16","article-title":"Total HIV-1 DNA, a marker of viral reservoir dynamics with clinical implications","volume":"29","author":"Avettand-F\u00e8no\u00ebl","year":"2019;","journal-title":"Clin Microbiol Rev"},{"key":"2023010801140837900_dkac362-B10","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-029960","article-title":"Cohort profile: the observational cohort for the study of dolutegravir in antiretroviral combination regimens (ODOACRE)","volume":"9","author":"Ciccullo","year":"2019;","journal-title":"BMJ Open"},{"key":"2023010801140837900_dkac362-B11","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/hiv.12468","article-title":"Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients","volume":"18","author":"Hoffmann","year":"2016;","journal-title":"HIV Med"},{"key":"2023010801140837900_dkac362-B12","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.3390\/v14051028","article-title":"Reversibility of central nervous system adverse events in course of ART","volume":"14","author":"Taramasso","year":"2022;","journal-title":"Viruses"},{"key":"2023010801140837900_dkac362-B13","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1124\/dmd.112.048918","article-title":"In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor","volume":"41","author":"Reese","year":"2013;","journal-title":"Drug Metab Dispos"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/78\/1\/117\/48444472\/dkac362.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/78\/1\/117\/48444472\/dkac362.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,8]],"date-time":"2023-01-08T01:14:23Z","timestamp":1673140463000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/78\/1\/117\/6770014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,22]]},"references-count":13,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,10,22]]},"published-print":{"date-parts":[[2023,1,5]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkac362","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,1,5]]},"published":{"date-parts":[[2022,10,22]]}}}